Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in...
Germany: Boehringer Ingelheim has announced it will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for people living with overweight or...
/PRNewswire/ -- Boehringer Ingelheim announced today that SENVELGO® (velagliflozin oral solution), a revolutionary new treatment for cats with diabetes, has...
Pyramid Technoplast aims to raise anywhere between Rs 139 crore - Rs 153 crore through the IPO, and the post implied market cap is likely to be around Rs 611 crore.